Just In
- 2 hrs ago Thrissur Pooram 2024: Date, Time, History, Significance, And Celebrations Related To Kerala's Rich Traditions
- 6 hrs ago Daily Horoscope, 19 April 2024: Gemini Will Have A Controversial Day In Terms Of Love
- 10 hrs ago Kamada Ekadashi 2024 Wishes: Greetings, Messages, Texts, Images, Twitter Status And Instagram Captions
- 11 hrs ago Deepika Padukone's 6 Refreshing Skincare Tips to Beat the Summer Heat
Don't Miss
- News Chhattisgarh CM Urges Bastar Residents To Vote In Large Numbers
- Movies Siren HD Leaked Online For Free Download Within Hours Of Its OTT Release
- Finance Rs 40/Share Dividend: Small Cap Under Rs 100 To Hit Ex-Date In 4-Days, Gains 74.21% In 1-Week
- Technology itel Super Guru 4G Phone With UPI Support Launched in India; Check Price, Specifications
- Sports Why camera zoomed in on IPL 2024 coin toss after Sam Curran flipped it in front of Hardik Pandya in Mullanpur?
- Automobiles India's Elections Trigger Airfare Surge in Tamil Nadu
- Education Karnataka SSLC Result 2024 Soon, Know How to Check Through Website, SMS and Digilocker
- Travel Telangana's Waterfall: A Serene Escape Into Nature's Marvels
Omicron May Not Evade All Monoclonal Antibodies, Lab Study Suggests
The Omicron variant of coronavirus may evade several, but not all, monoclonal antibodies used clinically to prevent patients from developing severe COVID-19, according to a laboratory study.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses.
Several past studies have shown that such antibodies are unsuccessful in neutralising Omicron.
The team led by researchers at Washington University, US, tested five antibody combinations, including those discovered at Vanderbilt University Medical Centre (VUMC) in the US.
The study, recently published in the journal Nature Medicine, found that antibodies, including those in clinical use by biopharmaceutical companies Celltrion, Regeneron and Eli Lilly, completely lost the ability to neutralise Omicron in cell culture.
The antibodies developed at VUMC had a reduced neutralising ability, while as an antibody developed by Vir Biotechnology, US, was minimally affected, the researchers found.
"Omicron escapes recognition by several of the monoclonal antibodies that are being used for therapy," said James Crowe director of the Vanderbilt Vaccine Center, whose team discovered the monoclonal antibodies at VUMC which were later optimised by AstraZeneca into an antibody combination called Evusheld.
"The precursor antibody of Vir Biotechnology's sotrovimab, and the prophylaxis antibodies in Evusheld retain substantial though reduced activity," said Crowe, coauthor of the research paper.
Although these data suggest that some monoclonal antibodies in clinical use might retain the benefit, more experiments are needed to support this conclusion and inform clinical decisions, the authors noted.
The loss of neutralising ability in Omicron is due to the more than 30 mutations in its "spike" protein, the antibody target on the surface of the virus which helps it to enter and infect cells.
The loss of inhibitory activity in the study is consistent with the observation that antibody responses generated after vaccination or natural infection also lose substantial inhibitory activity against Omicron, the researchers said.
That finding may explain in part the rise in symptomatic infections caused by the Omicron variant in people who have previously been vaccinated, they said.
The study "is good news, since we still have a least one antibody-drug we can use for each of the indications, prevention or therapy," Crowe added.
The continued identification and use of broadly and potently neutralising monoclonal antibodies that target the most highly conserved and least likely to mutate portions of the spike protein are needed to protect against Omicron and future variants, the researchers added.
- pregnancy parentingMysterious Pneumonia Outbreak In China: What Are The Long-Term Effects Of Pneumonia In Children?
- healthCan You Get Back COVID-Related Loss Of Sense Of Smell And Taste (Parosmia)? Looks Like You Can!
- healthDid Covid-10 Vaccination Increase Risk Of Sudden Deaths In Young Adults? ICMR Finds This..
- wellnessDelhi Air Pollution, Air Quality Very Poor: Do Covid Masks Help Reduce Pollution Side Effects?
- healthNobel Prize 2023: Scientists Behind The COVID-19 mRNA Vaccines Wins
- healthWhat Is Disease X? 20 Times More Deadlier Than Covid 19; Can Cause 50 Million Deaths, Does It Have Vaccine?
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- healthDo You Pick Your Nose? Stop! It Can Increase COVID Risk
- healthEris Variant: WHO Alarms New Covid Wave; Should India Be Concerned About This Pandemic
- healthVitamin D Deficiency Linked With Increased Risk Of Long COVID
- healthCOVID Surge In India: Do You Need A COVID-19 Booster Shot?
- healthCOVID-19: IMA Cites 3 Reasons Behind Recent Surge In Covid-19 Cases: What Are They?